Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3307888 | 1.00 | ALDH1A1 (0.47) | ALDH1A1TDP1POLBSRD5A2SRD5A1 | |
| SCHEMBL4441925 | 0.79 | HTR2A (0.38) | ALDH1A1AKR1C3KDM4ETSHR | |
| SCHEMBL25452840 | 0.78 | HTR2A (0.49) | SRD5A1 | |
| SCHEMBL3303931 | 0.77 | METAP1 (0.44) | SRD5A2SRD5A1KMT2A | |
| SCHEMBL3303935 | 0.77 | METAP1 (0.44) | SRD5A2SRD5A1KMT2A | |
| SCHEMBL3300861 | 0.76 | TDP1 (0.48) | ALDH1A1TDP1POLBSRD5A2SRD5A1 | |
| SCHEMBL3300853 | 0.76 | TDP1 (0.48) | ALDH1A1TDP1POLBSRD5A2SRD5A1 | |
| SCHEMBL10908324 | 0.75 | ACHE (0.51) | ALDH1A1TDP1SRD5A2SRD5A1 | |
| SCHEMBL24742783 | 0.75 | POLB (0.47) | ALDH1A1POLBSRD5A2SRD5A1KMT2A | |
| SCHEMBL30420549 | 0.73 | GRM5 (0.56) | ALDH1A1POLBSRD5A2SRD5A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309542-B2 | Substituted pyrrolidine amides, the production thereof, and the use thereof as medications | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2008135526-A1 | CARBOXYLIC ACID AMIDES AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008135524-A2 | SUBSTITUTED ANTHRANILAMIDES AND ANALOGUES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | DDC, GLS, UROD | ALDH1A1 562/4885TDP1 434/4885POLB 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.